Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
Status:
Suspended
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of stereotactic body radiation
therapy when given together with capecitabine before surgery in treating patients with
pancreatic cancer that can be removed by surgery. Stereotactic body radiation therapy may be
able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs used
in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving stereotactic
body radiation therapy and capecitabine before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed.